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1 Introduction 
 
1.1 General introduction 
 
Tissue engineering and cell-based therapies constitute emerging scientific areas in 
regenerative medicine with therapeutic fields of applications in disease management 
and research [1,2]. Tissue engineering is challenging, it basically implies cells, 
biomaterials and bioactive factors (Figure 1) [3]. 
For the engineering of surgical implants, which target the restoration of physiological 
tissue function and the promotion of tissue regeneration after injuries, adequate 
scaffolds are required [4-7]. The construction of such matrices is a major issue in tissue 
engineering. They contain porous structures with a large surface volume, which 
mechanically support cells upon in vitro expansion, rendering a function which is similar 
to the extracellular matrix in vivo. Cells can grow on scaffolds and are able to invade 
them because of the interconnected pores. Thus, 3 dimensional and tissue-like 
structures can be built in vitro. A wide variety of different permanent or biodegradable 
scaffolds have been described, which are either of natural origin or produced 
synthetically.  
 
 
Figure 1 Principle of tissue engineering1: Schematic overview. 
                                               
1
 source: http://www.bioeng.nus.edu.sg/research/keyrsch1.htm [online] 
Introduction 
2 
 
Much work has already been conducted with respect to sources of cells [6,8-14], 
including mature and differentiated cell types (e.g. epithelial cells, fibroblasts, 
chondrocytes) and undifferentiated, embryonic/adult stem cells. Many tissue 
engineering approaches use the benefits of stem cells, as they have a multilineage 
potential and can be differentiated into various cell types. Beside bone marrow derived 
mesenchymal stem cells (BM-MSCs), somatic stem cells isolated from adipose tissue 
(ASCs) have been proposed as a reliable source of autologous, multipotent cells for 
mesenchymal defect repair and wound healing [3,6,7,15-24,9,13,14,18]. Human 
adipose derived stem cells (hASCs) have a proven chondrogenic potential in vitro and 
in vivo [26-28]. Although, BM-MSCs and hASCs are very similar and share many 
properties, they are not identical and thus have to be studied separately. 
Concerning the lineage commitment of stem cells, microenvironment and culture 
conditions seem to play an important role. Hence, additionally to matrices and 
adequate cell sources, specific environmental factors such as growth factors and 
cytokines are required for the engineering of bioartificial tissues. They provide signals 
which control e.g. cell growth and -proliferation and affect the differentiation capacity of 
(stem) cells in a dosage-dependent manner [6,9, 21,29]. Human fibroblast growth 
factor 2 (hFGF-2), a strong morphogen and mitogen with pleiotropic effects on various 
tissues and organs, is one of such factors [30]. It is one of the most studied growth 
factors with clinically proven effects in wound healing [31,32]. 
 
Engineering of tissues like cartilage, bone, ligaments and tendons would be highly 
beneficial for the functional restoration after chronic and acute tissue damage (e.g. 
osteoarthritis, traumatic/degenerative bone or joint defects or soft tissue reconstruction 
after tumor surgeries) [25]. Despite all recent progresses in stem cell research and 
tissue restoration, a full characterization and understanding of adult stem cell 
properties is missing and generalized culture conditions still have to be defined [33]. 
For bringing stem cell-based therapies into clinical use and, in order to be able to 
manipulate cells in a predictable way, it is primarily of major importance to understand 
the underlying molecular mechanisms of stem cell regulation [18,34]. 
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1.2 Stem cells 
 
Stem cells are unspecialized cells, characterized by their capacity of self-renewal 
(clonogenity), longevity and the potential to differentiate along multiple cell lineage 
pathways [35,40]. Therefore, they are able to give rise to distinct and terminally 
differentiated cell types and tissues, which in turn render specific functions and 
characteristics [1,17,36]. Stem cells are found in fetal tissue, as well as in many adult 
tissues. It is believed that they are persisting throughout life within the body. By 
replacing damaged cells and thus restoring specific tissue function, stem cells are 
contributing to the maintenance of the normal physiological function of an organism 
[16,33,37,38].  
Although, the function of stem cells is not fully understood, their roles have been 
outlined especially 
- during embryonic development, by building 
 extra-embryonic tissue (e.g. the placenta) 
 embryonic tissue: specification of the three embryonic germ layers (ectoderm, 
endoderm, mesoderm) 
and  
- throughout life in adulthood 
 for continuous maintenance of natural cellular homeostasis 
 for tissue remodeling 
 by replacing damaged cells and tissues they contribute to adult tissue repair 
and regeneration, after injuries or tissue damage [10,16,33,39]. 
 
By definition, stem cells can be classified by their origin (e.g. embryonic stem cells, 
adult stem stems), respectively by their developmental potential (Figure 2): totipotent 
stem cells show the ability of forming any cell type and tissue of the body, including 
extra-embryonic tissue; pluripotent stem cells are capable of building all cell types, 
which arise from the three germ layers and multipotent stem cells, which can give rise 
to terminally differentiated and mature cell types of one lineage [10,40]. 
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Figure 2 Differentiation potential of stem cells2 
totipotent stem cells can be only isolated from the inner cell 
mass during early embryonic development (zygote), after 
gastrulation embryonic stem cells are considered to be 
pluripotent, multipotent stem cells give rise to different cells of 
one lineage, e.g. hematopoietic stem cells, which can 
differentiate into mature blood cells of the myeloid (monocytes, 
granulocytes, megacaryocytes etc.) and lymphoid 
(lymphocytes, natural killer cells etc.) lineage, unipotent 
progenitor cells, can mature into one distinct cell type (e.g. 
proerythroblasts). 
 
 
1.2.1 Embryonic stem cells 
 
Embryonic stem cells (ESCs) have firstly been isolated from the inner cell mass of 
blastocysts by Evans and Kaufman [41] and by Martins [42] in 1981. They are 
considered to be the least differentiated stem cells with a nearly unlimited proliferation 
capacity [1,36]. ESCs are totipotent, thus capable of forming a completely developed 
organism. However, as embryonic development progresses, their almost unlimited 
                                               
2
 source: http://virtuallaboratory.colorado.edu/Biofundamentals/lectureNotes/AllGraphics/stemcellcommittment.gif 
[online] 
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proliferation potential is restricted and after gastrulation ESCs are becoming pluripotent 
[10,33,40]. 
In spite of the promising therapeutic potential of ESCs they are, mostly due to ethical 
issues, discussed controversially [6,7,9,16,43]. In addition, problems like 
contamination, the need of genetic alterations, cell regulation, the 
tumorigenic/teratogenic potential of transplanted cells or the procurement of sufficient 
cell quantities, limit their field of clinical applications [1]. 
 
1.2.2 Adult stem cells  
 
Adult stem cells are needed for normal growth, as well as for tissue regeneration after 
acute or chronic tissue damage [12]. They are capable of differentiating into various 
distinct cell types and are responsible for tissue replacement after injuries, thereby 
helping to maintain tissue function and specificity [10,39,43]. Adult stem cells were 
originally isolated from the stroma of the bone marrow (BM) and were identified as 
multipotent osteoprogenitor cells [16,24,34,45-47]. Accordingly, these cells were 
classified as bone marrow derived mesenchymal stem cells (BM-MSCs). Many studies 
have demonstrated their ability to differentiate, after in vitro expansion and in the 
presence of specific differentiation- /growth factors, into mature fibroblasts, adipocytes, 
chondrocytes and myocytes [8-14,17]. Given that MSCs are able to transform into 
multiple mesenchymal cell lineages in vitro and in vivo, they appear to be an ideal 
population for mesodermal defect repair and tissue regeneration. However, drawbacks 
such as the painful and invasive isolation procedure (bone marrow aspiration), a low 
cell number harvest and high morbidity rates, confine their clinical use [15,17]. 
Since that, many reports have confirmed the presence of tissue-specific adult stem cell 
populations in almost all tissues of the body. So far, adult stem cells have been 
described for example in brain, bone marrow, peripheral blood, kidney, epithelia of the 
digestive system, skin, retina, muscles, pancreas, liver and adipose tissue 
[1,9,16,37,48]. 
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Adipose tissue 
Adipose tissue is highly complex, harboring multiple cell types, such as mature 
adipocytes/preadipocytes, fibroblasts, vascular smooth muscle cells, endothelial cells, 
monocytes/macrophages [49], lymphocytes [50] and, last but not least, a population of 
putative, multipotent stem cells [21,22]. Like BM-MSCs, stem cells isolated from 
adipose tissue, evolve from the embryonic mesenchyme (adipose derived 
mesenchymal stem cells, ASCs) [6,9,15,20,23]. They are capable of building all types 
of connective tissues within the body. Recently, it was shown that the differentiation 
potential of ASCs can be extended even across lineage boundaries, to ectodermal and 
endodermal tissues [7,24]. So far, ASCs were transformed already into osteogenic 
(bone) [3,6,9,13,17,24], adipogenic (fat) [3,6,9,13,17,21], myogenic (muscle) 
[3,6,9,13,17], chondrogenic (cartilage) [3,6,9,13,17,25,51], neurogenic (neurons), 
endothelial [6,13,18,24], hematopoietic [13,24] and cardiomyogenic [6, 24] cell 
lineages. 
 
Properties of MSCs 
Both, mesenchymal stem cells isolated from bone marrow and from adipose tissue, are 
of autologous origin and therefore immuno-compatible. They show a low tumorigenic 
potential and only minimal ethical restrictions accompany their use [1,6,9,10,13,52]. 
BM-MSCs and ASCs are not identical, but they display similar phenotypes, intrinsic-, 
angiogenic-, anti-inflammatory properties and differentiation capacity 
[6,9,15,18,19,23,53]. MSCs can be cryopreserved and are expanded easily in poor 
culture media [18]. They grow in clusters in monolayer-cultures, are adherent to plastic 
surfaces and are highly sensitive to trypsin [12,13,23,43]. In culture, MSCs 
progressively lose their differentiation capacity and become senescent after 15–50 
doublings (variations are due to donor-to-donor differences) [12,34]. Phenotypically, 
BM-MSCs and ASCs exhibit a fibroblast-like, spindle-shaped morphology, although 
ASCs are slightly smaller (Figure 3) and are able to achieve higher passage numbers 
before becoming senescent [26].  
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Figure 3 Fibroblast-like morphology of hASCs 
Light microscopic picture of hASCs in passage 1, 
cells cultured in DMEM Ham´s F12 medium, 100x. 
 
Human adipose derived stem cells (hASCs)  
Human adipose derived stem cells are somatic stem cells of mesenchymal origin. 
Much effort was dedicated recently with regard to the isolation procedure, expansion 
and differentiation of hASCs [54]. Clinically they were applied for the first time in 
calvarial bone defects (the superior portion of the skull) [55].  
Many advantages in the practical use of hASCs have been proposed. First of all, hASC 
are abundant, accessible and replenishable. The stem cell number in adipose tissue is 
significantly higher (2%) compared to bone marrow (0.002%) [24]. Procurement of 
hASCs by liposuction/lipoaspiration is surgically speaking easy, much less invasive, 
repeatable and brings less discomfort for the patient than bone marrow aspiration. 
Applications are not restricted due to low cell quantity and only minimal morbidity rates 
have been observed upon harvest [6,9,15,17,18,21-24]. 
Among many other findings which concern the functional and physiological effects of 
hASCs in vitro and in vivo, it was discovered that uncommitted hACS promote tissue 
regeneration and wound healing, by secretion of angiogenic and anti-apoptotic 
cytokines and growth factors [21,56]. They can undergo osteogenesis in vitro and it 
was also shown in an ectopic bone model, that hASCs are able to form bone in vivo 
[24]. Furthermore, hASCs are able to build and deliver extracellular matrix components, 
which are vital in engineering of structural elements and connective tissues [1,3,7,8,24, 
37]. 
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1.3 Fibroblast growth factor 
 
Human fibroblast growth factor 2 (basic FGF, bFGF, FGF-2) belongs to the family of 
the heparin-binding factors. Human FGF-2 (hFGF-2) is produced by a variety of 
different cell types with notable differences in its tissue distribution and concentration 
[57]. It was one of the first family members to be identified already in 1982, along with 
the closely related homolog FGF-1 (acidic FGF, aFGF). Human FGF-1 and hFGF-2 are 
assigned as embryonic inducers with strong mitogenic activities [30,58-60].  
To date, this constantly growing family of growth factors constitutes over 20 related 
polypeptides. Family members are between 150 and 270 amino acids (aa) long and 
share a conserved central region of 144 aa [30,61]. The hFGF-2 gene is located on 
chromosome 4. It is 56 kb long, containing 3 exons and 2 introns [59,62]. After 
transcription of a single mRNA, different hFGF-2 isoforms can be produced by 
alternative translation. There are 4 high molecular weight (HMW) hFGF-2 forms with 
22, 22.5, 24, 34 kDa, and 1 low molecular weight (LMW) hFGF-2 of 18 kDa. [30,63,64]. 
The different hFGF-2 isoforms lead to different and specific cell phenotypes. Usually 
cells are able to produce all hFGF-2 forms [57,59]. 
 
High molecular weight hFGF-2 forms are residing in the nucleus, acting in a 
FGF-receptor (FGFR) independent manner. Their expression is directly linked to cell 
growth and proliferation, although cell migration is not changed upon its expression 
[30,59,62]. 
 
Low molecular weight hFGF-2 (18 kDa) serves as an autocrine, extracellular signaling 
molecule. Intracellular, LMW hFGF-2 is located in the cytoplasm. LMW hFGF-2 
interacts with 4 specific, transmembrane FGF-receptor tyrosine kinases (FGFR1, 
FGFR2, FGFR3, FGFR4). Via FGFR activation, downstream signaling pathways linked 
to cell proliferation and differentiation can be altered [30,57,59,60,62,65]. LMW hFGF-2 
expression leads to enhanced cell migration and mitogenesis. 
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Human FGF-2 (Figure 4) shows high affinity to heparin sulfate and heparin sulfate 
proteoglycans. Binding of heparin is important for the functional activity of hFGF-2, 
resulting in conformational changes, which protect hFGF-2 from proteolysis or 
denaturation and thus increases the biological half life of hFGF-2 [66,67]. 
 
Properties of hFGF-2 
Human FGF-2 is regulating basic cellular functions in cells of mesenchymal, endo- and 
ectodermal origin [30,58,68]. Its strong chemotactic and mitogenic properties makes it 
an important molecule for both, differentiation processes during early stages of 
development and for tissue remodeling [51,58]. It is implicated in angiogenensis by 
controlling cell migration, endothelial cell proliferation and tubulogenesis [59]. Human 
FGF-2 was also found to be engaged in invasive cell spreading during tumorigenesis. It 
regulates self-renewal of embryonic-, hematopoietic- and neuronal stem cells [69]. 
Further observed effects of hFGF-2 are [30,57,58]: 
 
 stimulation of cell proliferation and differentiation (e.g. in fibroblasts, 
osteoblasts, endothelial- and epithelial cells) 
 morphogenic modulation of the cellular phenotype 
                                               
3
 source: European Bioinformatics Institute: http://www.ebi.ac.uk/ [online] 
Figure 4 Three dimensional structure of hFGF-23 
Human FGF-2 is build by 3 connected groups of 11 antiparallel beta 
strands. Alpha helical structures are linking the residues 130 and 137, 
which are part of the heparin binding site. 
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 modulation of extracellular matrix components, organization of 
cytoskeleton 
 delay of cell senescence 
 stimulation of  hematopoiesis 
 impact on the function of the nervous system, eye and skeleton 
 the promotion of wound healing, tissue repair and melanogenesis 
 
MSCs are highly sensitive to hFGF-2 treatment in vitro. Therefore, hFGF-2 can be 
added as supplement to cell culture medium for optimization of the proliferation 
capacity [14,70]. It was shown that hFGF-2 helps to maintain the stem cell properties of 
MSCs and it enhances cell expansion during culture. Reports confirmed an increased 
chondrogenic lineage commitment of MSCs in the presence of hFGF-2 [26,34]. In 
hASCs, adipogenesis and chondrogenesis (induction of cartilage synthesis) was 
induced, whereas osteogenesis was inhibited by hFGF-2 treatment [25,51,70,71]. 
Other studies gave account of osteoblast and neuronal induction by hFGF-2 [43,65] in 
vitro, with some evidence of in vivo bone generation [34,40,70]. In animal studies, its 
role in healing of tendons and ligaments was outlined [8].  
 
Contradictory data illustrate the complexity of hFGF-2 associated molecular 
mechanisms. Effects of hFGF-2 are strongly influenced by culture conditions, 
microenvironment and the applied dosage. Proliferation always seems to be up-
regulated, accompanied with a change in cell size (hFGF-2 treated cells appear to be 
approximately 30% smaller), morphology and increased life spans of treated cells 
[15,34]. 
 
Recombinant, human FGF-2 constructs 
Human FGF-2 constitutes a binding site for fibrin and fibrinogen near the C-terminus, 
which has already been described by Sahni et al., 1998 [72] and Peng et al., 2004 [73]. 
After injuries, thrombin converts fibrinogen into fibrin. Thereby a temporary, structural 
matrix is provided, which supports local tissue healing. Human FGF-2 is also present at 
sites of injuries. It is suspected that the interaction between fibrinogen/fibrin and   
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hFGF-2, localizes hFGF-2 to sites of injuries. By that means, endothelial cell response 
and vascular repair can be coordinated. 
By use of commercially available fibrin sealant products, which consist of fibrinogen 
and thrombin, fibrin-based clots can be formed in vitro. Originally, these natural 
sealants or glues were developed for the support of homeostasis after injuries and 
wound care. However, fibrin-based clots can be utilized also as biodegradable 
scaffolds in tissue engineering [74]. A new approach in this context is the construction 
of truncated hFGF-2 variants, which are containing the fibrinogen binding site. Thereby 
drugs could be linked via hFGF-2 to fibrinogen and, after implantation, would be 
released slowly in vivo from the fibrin matrix. Ideally, truncated hFGF-2 variants should 
be as small as possible; containing only just the binding site. However, it was shown 
already that a stable interaction between hFGF-2 and fibrinogen/fibrin depends on 
more than only the binding site. The optimal/minimal length of such construct remains 
to be determined. Two such hFGF-2 variants (FGF-s3 HIS, FGF-2 HIS, Figure 5), 
which show a high binding affinity to fibrin, have been synthesized previously [61]. In 
this work they were tested in comparison to commercially available recombinant human 
FGF-2 (rhFGF-2). 
 
 
 
 
Figure 5 Recombinant hFGF-2 constructs  
 Constructs are containing the 15 aa binding domain for fibrinogen. 
FGF-s3 HIS truncated rhFGF-2, 156 bp; FGF-2 HIS full length 
rhFGF-2, 486 bp. 
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Aim of the study 
 
The overall aim of this study was to examine the effects of exogenously added human 
recombinant fibroblast growth factor 2 (rhFGF-2) on human adipose derived stem cells 
in vitro. Following questions were to be answered: 
 
1. Which differences in cell morphology, proliferation, apoptosis rates, cell viability and 
-density can be observed, when cultivating hASCs with hFGF-2 at varying 
concentrations? 
2.  Which dosage of hFGF-2 should be added to hASCs for optimal proliferation and 
differentiation? 
3. Does the hFGF-2 concentration affect the differentiation potential, respectively 
lineage commitment of hASCs? 
 
Additionally, the biological activity of two self-produced hFGF-2 constructs of varying 
sizes, which are containing the fibrinogen binding site, was determined: a.) FGF-2 HIS, 
a full length rhFGF-2 and b.) FGF-s3 HIS, a shorter truncated rhFGF-2 variant, both 
containing a 6x His tag tail. 
4. Are the results similar to the commercially available control peptide (rhFGF-2, 
Peprotech, UK)? 
5. What effect has the truncated FGF-s3 HIS fragment on hASCs regarding cell 
morphology, apoptosis rates, proliferation, cell viability and differentiation potential? 
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2 Materials and methods 
 
2.1 Materials 
 
Cells and media 
hASCs human adipose derived stem cells, Red Cross Blood 
Centre/Ludwig Boltzmann Institute for Experimental and 
Clinical Traumatology (Linz/Vienna, Austria) 
DMEM Ham`s F12 Dulbecco`s modified Eagles medium Ham`s F12, Sigma-
Aldrich (Vienna, Austria), 1% PenStrep, 10% FCS, 
2 mM L-glutamine 
 
 
Supplements 
PenStrep penicillin-streptomycin solution, stabilized, 
Sigma-Aldrich (Vienna, Austria) 
FCS fetal calf serum, Cambrex (Verviers, Belgium) 
L-glutamine 200 mM, Sigma-Aldrich (Vienna, Austria) 
 
 
Growth factors  
rhFGF-2 recombinant human FGF-2 (rhFGF-2, 462 bp), Peprotech 
(UK)  
FGF-2 HIS rhFGF-2 (486 bp), containing a 6x His-tag tail 
FGF-s3 HIS truncated rhFGF-2 (156 bp) 
Materials and methods 
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2.1.1 Solutions and chemicals 
 
ddH2O double distilled water, Mayrhofer Pharmazeutika GmbH 
(Leonding, Austria) 
10x PBS phosphate buffered saline, BioWhittaker Europe (Belgium) 
10x Trypsin 0.5% porcine trypsin, Sigma-Aldrich (Vienna, Austria) 
DMSO dimethyl sulfoxid, sterile filtered, Fluka (Buchs, 
Switzerland) 
EDTA ethylenediaminetetraacetic acid, VWR (Darmstadt, 
Germany) 
Tris base AppliChem (Darmstadt, Germany) 
1 M H2SO4 sulfuric acid, Fluka (Buchs, Switzerland) 
Trypan blue 
solution 
0.05 g trypan-blue, add 100 mL 0.9% NaCl, Merck 
Chemicals (Vienna, Austria) 
MTT [3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium 
bromide], Merck Chemicals (Vienna, Austria),  
stock solution: 5000 mg/L, working solution: cell culture 
medium with 650 mg/mL MTT 
10x TBE Buffer 108 g Tris, 55 g boric acid, 40 mL 0.5 M EDTA, pH 8, add 
1 L ddH2O 
Lipopolysaccharide  LPS from Escherichia coli serotype O26:B6, 1 mg/mL 
stock solution, diluted 1:1000 in ddH2O to a final 
concentration of 1 µg/mL 
 
Molecular biology 
DEPC diethyl pyrocarbonate, Fluka (Buchs, Switzerland) 
0.1% DEPC-treated  
water 
100 µL DEPC in 100 mL ddH2O, incubated o/n at 37°C, 
sterilized at 121°C, 1 bar, 20 min 
Agarose  Biozym (Oldendorf, Germany) 
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Ethidium bromide 10 mg/mL in ddH2O, Sigma- Aldrich (Missouri, USA) 
XCFF xylene cyanol FF, DNA 10x gel-loading Dye, 
Sigma-Aldrich (Vienna, Austria) 
6x XCFF gel loading  
buffer 
0.025% XCFF, 30% Glycerine, in 10 mM Tris pH 8.0, for 
DNA fragments < 1000 bp 
3 M NaAc sodium acetate, VWR (Darmstadt, Germany), 3 M in 
DEPC-treated water, adjusted to pH of 5.2 with 3 M 
acetic acid, sterilized at 121°C, 1 bar, 20 min  
Ethanol absolute p.a. Sigma-Aldrich (Missouri, USA) 
70 Vol% EtOH-DEPC 70 mL ethanol absolute, diluted with 30 mL DEPC-
treated water 
2-propanol Fluka (Buchs, Switzerland) 
Oligo-dT15 stock solution of 1 µg/µL, MWG- Biotech AG (Ebersberg, 
Germany) 
β-Mercaptoethanol Sigma-Aldrich (Vienna, Austria) 
dNTP mix (100mM) deoxynucleotide mix, lyophilized primers were 
reconstituted with DEPC-treated water to a 100 mM 
Stock, PeqLab (Erlangen, Germany), stored at -20°C. 
10 mM dNTP-DEPC 100 mM dNTP stock diluted 1:10 in DEPC- treated water 
to obtain a final concentration of 10 mM, stored at -20°C 
1.5% agarose gel 0.45 g agarose in 30 mL 1 x TBE buffer, plus 1.2 µL 
ethidium bromide 
 
DNA molecular weight markers: 
GeneRuler™ DNA Ladder, Fermentas (St.Leon-Rot, Germany) 
Low Range  1500 – 50 bp: 1500 bp, 850 bp, 400 bp, 200 bp, 50 bp 
Middle Range 5000 –1000 bp: 5000 bp, 2000 bp, 850 bp, 400 bp, 100 bp 
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PCR primers (Table 1) 
Primer stock  MWG Biotech (Ebersberg, Germany), lyophilized primers 
were reconstituted with ddH2O to a concentration of 100 µM 
and stored at -20°C. 
Primer s/as mix 10 µm sense (forward) + 10 µm antisense (reverse) Primer 
in ddH20, 10 µM 
 
 
 
Table 1 DNA primers for RT PCR analysis 
Tm: melting temperature, s: sense primer, as: anitsense primer 
1 collagen type 1, a2 (COL1a2), 2 collagen type 1, a1 (COL1a1), 3  collagen type 
3 (COL3), 4 vimentin (VIM), 5 desmin (DES), 6 alpha-smooth muscle actin 
(aSMA), 7 glycerinealdehyde-3-phosphate dehydrogenase (GAPDH). 
 
2.1.2 Biological kits and enzymes 
 
BrdU Cell Proliferation ELISA BrdU (colorimetric) Kit, 
Roche (Vienna, Austria) 
RNA Isolation GenElute Mammalian Total RNA Miniprep Kit, 
Sigma-Aldrich (Vienna, Austria) 
Desoxyribonuclease I RQ1 RNase-Free Dnase 1 U/µL, 10x DNase 
reaction buffer, stop solution, Promega (Madison, 
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WI, USA) 
DNA Polymerase Taq DNA Polymerase, 10x reaction buffer without 
MgCl2, 25 mM MgCl2 solution, Sigma-Aldrich 
(Vienna, Austria) 
AMV reverse transcriptase  1000 U, plus 5x buffer, Promega (Madison, 
WI, USA) 
Apoptose Detection Kit  
 
Annexin-V-Fluos Staining Kit plus sample buffer, 
Roche (Vienna, Austria) 
 
2.1.3 Devices and equipment 
 
Eppendorf reaction 
tubes 
1.5 mL, 2 mL, sterile, Greiner Bio-One 
(Kremsmünster, Austria)  
PCR reaction tubes Greiner Bio-One (Kremsmünster, Austria) 
Pipettes  5, 10 and 25 mL, Sterilin, Dr. Bertoni (Vienna, Austria) 
 2-10 µL, 20-200 µL, 200-1000 µL, Gilson (Limburg-
Offheim, Germany) 
Filter tips, sterile 1-100 µL and 200-1000 µL; Greiner Bio-One 
(Kremsmünster, Austria) 
Tissue culture plates 6-, 96-well plates Corning Life Science (Schiphol-Rijk, 
The Netherlands) 
Polypropylene tubes 15 mL, 50 mL, Greiner Bio-One (Kremsmünster, 
Austria) 
Tissue culture flasks  150 cm2, 75 cm2, Greiner Bio-One Cellstar 
(Kremsmünster, Austria) 
Neubauer haemacytometer Marienfeld Germany (Lauda-Königshofen, Germany) 
CryoS PP tubes Greiner Bio-One (Kremsmünster, Austria) 
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PP-Tubes 5 mL, Greiner Bio-One (Kremsmünster, Austria)  
Multichannel pipette 25-300 µL, Micronic-Systems (Lelystad, Netherlands) 
Heraeus megafuge 
1.OR Centrifuge  
Heraeus Holding GmbH (Hanau, Germany) 
Eppendorf Centrifuge 5415R Eppendorf AG (Hamburg, Germany) 
Thermomixer  TGradient Thermoblock, Biometra (Goettingen, 
Germany) 
Thermocycler  Tpersonal, Biometra (Goettingen, Germany) 
Pipetboy Hirschmann Laborgeräte, Roth (Karlsruhe, Germany) 
Laminar flow hood Biohazard UVUB 1200, Uniflow, KR-125 Safety, 
Uniequip (Munic, Germany) 
Incubator 37°C, 5% CO2, Binder (Tuttlingen, Germany) 
Microscope Zeiss Axiovert 10 (10x, 20x, 50x), Carl Zeiss (Jena, 
Germany) 
Plate Reader SLT Spectra, Software: BIOLISE 
FACS  Fluorescence activated cell sorter 
 
 
 
 
Cytomics FC 500 MPL, Beckman Coulter (Fullerton, 
USA) 
Software FACS MXP Cytometer/ Analysis, Cytometer 
RXP Analysis 
Photometer Smart Spec™ 3000, Biorad; Hercules (CA, USA) 
Electrophoresis Chamber ComPhor L Mini, BIOzym (Hamburg, Germany) 
Powersupply Power Pac 300, Biorad (CA, USA) 
ChemiImager4400 
Fluorescence 
BIOzym (Hamburg, Germany), Software: Alpha 
Innotech Corporation (CA, USA) 
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2.2 Methods 
 
2.2.1 Experimental design 
 
Human adipose derived stem cells were incubated for 28 days in 6-well/96-well plates. 
The activity of a self-produced and purified FGF-2 HIS protein and a shorter rhFGF-2 
variant (FGF-s3 HIS) was tested and compared with a commercially available rhFGF-2 
(Peprotech, UK) protein. Samples were collected on days 7, 14, 21 and 28 (Figure 6). 
Growth factors were added to the media in two concentrations: low dose (3 ng/mL) and 
high dose (30 ng/mL). As reference, cells were cultured without hFGF-2 supplements. 
During the time period of 28 days, medium was changed once a week. On the selected 
time points (days 7, 14, 21, 28) cell viability, proliferation status, percentage of 
apoptotic cells, differentiation and cell density was analyzed.  
 
Figure 6 Experimental design of the study 
Cell culture media supplements: rhFGF-2, FGF-2 HIS, FGF-s3 HIS. 
Low-/high dose: concentration of cell culture media supplements.  
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2.2.2 Cell culture methods 
 
Harvesting cells 
Cells were isolated by enzymatic digestion (collagenase treatment) from human 
adipose tissue after liposuction at the Red Cross Blood Centre/Ludwig Boltzmann 
Institute for Experimental and Clinical Traumatology (Linz/Vienna, Austria). The cells 
were seeded on culture dishes and subsequently harvested and cryopreserved. In the 
experiments hASCs isolated from 5 different, middle-aged donors were tested.  
Human ASCs grow in monolayer on the plastic surface of culture flasks. In order to 
dissociate and harvest the isolated hASCs, they were trypsinized with 0.5% trypsin, 
diluted 1:4 in 1x PBS, for 5–8 minutes at 37°C. Trypsin was inactivated by adding an 
equal volume of medium and the cells were harvested by centrifuging at 180 g for 5 
min at room temperature (RT). The cell pellet was resuspended in 2 mL cell culture 
medium.  
 
Cell culture 
Human adipose derived stem cells were cultivated in tissue culture flasks to a 
maximum confluence of 70-80%. The cells grew at 37°C and 5% CO2 in DMEM Ham`s 
F12 medium, supplemented with 10% FCS, 1% PenStrep and 2 mM L-glutamine. 
Medium was changed twice a week. For the experiments cells were used up to 
passage 4 after isolation. The experiments were repeated 5 times (n = 5) with hASCs 
from different donors.  
All steps were carried out under sterile conditions in a Laminar flow cabinet, using 
sterilized equipments and solutions. 
 
Determination of cell number: Haemocytometer counting and trypan blue 
staining 
The trypan-blue staining is a simple and commonly used method to count cells in 
suspension. It also allows the determination of the percentage of viable and non-viable 
cells in the preparation. Trypan is an acidic dye, which is absorbed by cells with 
damaged cell membranes (non-viable cells), though it cannot pass through intact 
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membranes of living cells. Hence, it accumulates in dead cells, selectively staining 
them blue (dye exclusion method) [76-78].  
 
Procedure  
1. Depending on the size of the cell pellet, an aliquot of the dissociated cell 
suspension was diluted 1:2/1:10 with 0.5% trypan-blue solution, and filled into a 
Neubauer haemocytometer (Figure 7). 
2. The total cell number of the four corner primary squares was counted and the total 
cell concentration in the original cell suspension was calculated as follows: 
cells/mL = total count x 104 x dilution factor 
 
 
 
Figure 7 Neubauer haemocytometer4: Schematic picture. 
 
Seeding 
In total, for each run, 2.35 x 105 hASCs were required (Table 2). The cell suspensions 
were prepared separately in 50 mL polypropylene tubes (1-14, Table 3). Samples for 
cell viability (MTT) and proliferation (BrdU) tests were seeded in triplicates into 96-well 
plates, containing 150 cells and 100 µL medium per well. Samples for cell counts, 
                                               
4
 source: http://www.laborwissen.de/old_hp/fachbereiche/hama/methoden/neubauer.php [online] 
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apoptosis (Flow cytometry) and differentiation (RT-PCR) analysis were seeded into 6-
well plates, whereas only the wells for day 7 were seeded in triplicates, containing 
5.103 cells and 3 mL of medium per well.  
 
 
Table 2 Overview of cell numbers per experiment 
 
 
 
Table 3 Prepared cell suspensions 
 
 
2.2.3 Molecular biological methods 
 
Total RNA isolation from cells 
Cells were lysed by removing the medium and adding 250 µL of lysis buffer, containing 
1% β-mercaptoethanol, to each well. Samples were incubated for 2 min on a plate 
shaker before proceeding with the RNA isolation, according to the instruction manual of 
Genelute Mammalian RNA-Miniprep-Kit (Sigma-Aldrich). RNA was eluted with 50 µL 
RNase free water (elution buffer). During the following steps, samples were stored on 
ice. 
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Determination of RNA concentration 
For determination of the RNA concentration, 5 µL of each sample was diluted 1:20 with 
RNase free water (elution buffer) to measure the optical density (OD) at 260 nm/280 
nm. 
 
DNase I treatment 
To the remaining 45 µL RNA, a 1/10 volume of 10x DNaseI reaction buffer (4.5 µL) and 
4.5 µL DNaseI (4.5 U) was added. After 30 min incubation at 37°C the reaction was 
stopped by adding a 1/10 volume of stop solution (5.4 µL). 
 
NaAc/EtOH precipitation 
A 1/10 volume of 3 M NaAc, pH 5.2 and 2.5 volumes of 100% EtOH were added. The 
samples were incubated for at least 30 min, up to overnight (o/n), at -80°C. RNA was 
precipitated by centrifuging for 40 min at 14.000 g and 4°C in a pre-cooled centrifuge. 
The pellets were washed with 1 mL 70% EtOH (diluted in DEPC-treated water), 
centrifuged again for 5 min at 13.000 g and 4 °C and air dried. 
 
Reverse transcription (RT, cDNA Synthesis) 
Dry pellets were dissolved in 10 µL Oligo-dT15 Mix (9 µL DEPC-treated water + 1 µL 
0.5 µg/mL OligodT15), incubated for 5 min at 70°C and immediately cooled on ice 
(“snapcooling”, annealing Oligo-dT primer). To each sample 15 µL AMV-mastermix 
was added, containing 6 µL DEPC-treated water, 5 µL 5x AMV buffer, 2.5 µL 10mM 
dNTP mix (diluted with DEPC-treated water) and 1.5 µL (15 U) AMV-reverse 
transcriptase. Samples were incubated for 1 h at 42°C, 2 min at 95°C and stored at      
-20°C until further procedure.  
 
Polymerase chain reaction 
The PCR-mastermixes were prepared as described in Table 4. The DNA Taq-
polymerase was added at the end. A volume of 23 µL was transferred into PCR 
reaction tubes and 2 µL of the respective primer s/as mix (10 µM) were added. DNA-
amplification was performed in a thermocycler. Table 5 shows the set up of the 
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temperature program and Table 6 the product sizes of DNA-amplicons and the melting 
temperatures (Tm) of the primers. The housekeeping gene glycerinealdehyde-3-
phosphate dehydrogenase (GAPDH) was used as reference, as it is expressed 
continuously in cells without up- or down-regulation. 
 
 
PCR-Mastermix 
 
1x  
[µL] 
8x  
[µL] 
DEPC-treated water 16.8 134.4 
10x Buffer 2.5 20.0 
MgCl2 2.0 16.0 
dNTP-DEPC (10 mM) 1.0 8.0 
template 0.6 4.8 
Polymerase 0.1 0.8 
total 23.0 184.0 
Primer s/as mix (10 µM each) 2 
 
Table 4 PCR-mastermix 
 
 
Table 5 PCR-cycle program 
 
 
Table 6 Product sizes and melting temperatures of PCR-primers 
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Agarose gel electrophoresis 
An amount of 0.45 g agarose was dissolved in 30 mL TBE-buffer by heating (1.5% 
agarose gels). Ethidium bromide was added to a final concentraion of 0.4 µg/mL      
(1.2 µL). After polymerization, the PCR products were mixed with 5 µL 6x XCFF gel 
loading buffer. 2 µL of a DNA molecular weight marker (GeneRuler™ DNA Ladder, 
Fermentas) and 10 µL of the samples were transferred into the gel pockets. Gel 
electrophoresis was run for 25 min with 120 Volt (V).  
 
Detection and quantification 
DNA bands were detected by UV-light irradiation in a ChemiImager. For semi-
quantitative analysis the densitometric values of the PCR bands were determined with 
the ChemiImager 4400 software (Alpha Innotech Corporation). The expression levels 
were calculated by dividing the results by the values of GAPDH. 
 
 
2.2.4 Flow cytometry 
 
By use of flow cytometry, cells are counted and separated, in order to study specific 
cell types or disease condition. Specific populations and subpopulations of a given 
sample can be defined and even isolated, by combining this system with a dedicated 
cell sorter (fluorescence activated cell sorting- FACS). Characterization of cells can be 
carried out in different ways: either by measurement of cellular/physical properties of a 
cell, such as granulation and cell size, or by determination of specific cell surface 
markers, using fluorescence labeled antibodies. It is possible to measure multiple cell-
surface markers simultaneously, if different fluorescence labeled antibodies are 
available (Figure 8) [79-81]. 
Basically a flow cytometer consists of a flow cell, which contains the cell suspension 
and a sheath fluid, an optical system with a light source (e.g. a laser beam) and a fixed 
detector off the light source (Figure 9). The cell suspension is transported through a 
capillary in a fluid stream. Single cells pass a laser beam and changes in light 
(scattered, absorbed or emitted light- visible or fluorescent light emissions) are 
measured by a detector. All light signals are converted into digital signals and 
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consequently displayed in histograms or dot blot diagrams. Regarding the cellular 
properties, it has to be noted, that forward scattered light correlates with the cell size, 
whereas sideward scattered light is an indicator for the granulation of a cell. 
 
 
 
Figure 8 Fluorescence dyes: Emission spectrum5 
FL fluorescence channel, fluorescent dyes: FITC fluorescein-iso-thiocynanat, peak emission 
wavelength at 519 nm - FL1, PE R-phycoerythrin, peak emission wavelength at 578 nm - FL2, 
Cy5 reactive fluorescent dye, belonging to the cyanin dye family PE-Cy5: PE coupled with Cy5, 
peak emission wavelength at 670 nm. 
                                               
5
  source: [79] 
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Figure 9 Schematic buildup of a flow cytometer6 
A sample/cell suspension is transported in capillaries to the flow chamber. In the flow chamber 
cells are aligned, one after another, and presented to the laser using principles of 
hydrodynamic focusing. 
 
Detection of apoptosis by ANNEXIN V/PI staining 
Upon early stages of apoptosis, changes of the cell surface properties take place. 
Among others, they are characterized by translocation of phosphatidylserine (PS) from 
the inner side of the plasma membrane to the external cell surface. Annexin V is a Ca2+ 
dependent phospholipid-binding protein, which binds to PS and therefore can be used 
for the detection of early apoptotic cells. Necrotic cells likewise bind Annexin V, though 
the mechanism is different: upon necrosis, cell membranes lose their integrity, become 
leaky and Annexin V can bind to PS by entering the cell. Propidium iodide (PI) is a 
DNA intercalating, fluorescent molecule, which can only pass through defect cell 
membranes of necrotic or late apoptotic cells. Annexin V/PI double staining enables 
discrimination of necrotic and early apoptotic cells (Table 7 and Figure 10) [82-85].  
                                               
6
 source:[80] 
 
Materials and methods 
28 
 
 
Figure 10 A typical histogram after Annexin V/PI double staining 7 
X-axis Annexin V positive cells, FL1, Y-axis Propidium 
iodide positive cells, FL2. 
 
 
Annexin PI 
living cells negative negative 
apoptotic cells positive negative 
necrotic/late apoptotic cells positive positive 
Table 7 Annexin V/PI staining 
Discrimination of viable, apoptotic and necrotic cells by Annexin V/PI double staining. 
 
 
Procedure: 
Cells were trypsinized, washed with 1x PBS and centrifuged for 5 min at 180 g and RT. 
The supernatant was discarded carefully and cells were resuspended in 100 µL binding 
buffer. As positive control, 1 µg/mL lipopolysaccharide (LPS) was added and incubated 
for 4 hours at 37°C. Cells were stained by adding 2 µL Annexin V-FITC and 1 µL PI 
and incubated for 15 min at RT in the dark. For analysis, 400 µL binding buffer was 
added and cells were measured with a Beckman Coulter Flow Cytometer (Cytomics FC 
500 MPL), and analyzed (Software: FACS MXP Cytometer/Analysis, Cytometer RXP 
Analysis). Annexin was measured at 492 nm in fluorescensce channel 1 (FL1) and PI 
at 370/550 nm in fluorescence channel 2 (FL2). 
                                               
7
 source: [83] 
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2.2.5 BrdU enzyme-linked immunosorbent assay (ELISA) 
 
The BrdU ELISA is a colorimetric, cellular immunoassay, which enables quick, simple 
and exact analysis of cell proliferation, based on the quantification of DNA-synthesis. 
Bromodeoxyuridine (5-bromo-2-deoxyuridine, BrdU) is a thymidine analogue and thus 
can be incorporated in replicating cells in place of thymidine into the newly synthesized 
DNA strand. The incorporation of BrdU is measured by means of a peroxidase-
conjugated mouse mononuclear antibody directed against BrdU (anti-BrdU-POD). The 
binding is achieved by denaturation of DNA, no cross-reactivities with other cellular 
components (e.g. thymidine, uracil) are observed. Only proliferating cells incorporate 
BrdU into DNA. For immune-detection, 3,3´,5,5´-tetramethylbenzidin (TMB) is used as 
substrate. It has to be noted, that Bromodeoxyuridine is a known carcinogen 
(Figure 11) [86,87]. 
 
 
Figure 11 Test principle of the BrdU ELISA8 
Colorimetric cell proliferation ELISA BrdU Assay, Roche (Vienna). 
FixDenat solution for fixation of cells and denaturation of DNA 
TMB 3,3´,5,5´-tetramethylbenzidine. 
 
                                               
8
 source: Roche-Applied Science (2010): http://www.roche-applied-science.com/proddata/gpip/3_5_3_21_1_8.html. 
[Online]  
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Procedure: 
Cultivated hASCs (96-well plates) were labeled with BrdU by adding 10mM BrdU-
labeling solution (10 µL/well) to the medium and incubated o/n at 37°C and 5% CO2 in 
the incubator. In order to expose BrdU for immunodetection, cells were fixed and 
genomic DNA was denaturated for 30 min at RT in the dark with FixDenat-solution 
(100 µL/well). The BrdU label was detected with an anti-BrdU-POD antibody 
(100 µL/well), diluted 1:100 in cell culture medium. After an incubation of 90 min at RT 
in the dark, plates were washed 3x with 200 µL washing solution. 100 µL TMB-
substrate-solution was added (substrate reaction) and incubated for 25 min at RT in the 
dark. The reaction was stopped with 25 µL 1 M H2SO4 per well (color change from 
yellow to blue). Finally, plates were incubated for 1 min on a plate shaker and the 
extinction was measured immediately at 450 nm (reference: 620 nm) [87]. 
 
2.2.6 MTT test 
 
The MTT test measures cell activity by analysis of mitochondrial metabolism. MTT 
[3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide] is a yellow, water-
soluble dye, which is reduced in the mitochondria of active cells by NADH/NADPH to 
the blue-violet, water-insoluble Formazan. By addition of organic solvents, e.g. 
Dimethylsulfoxide (DMSO), Formazan is dissolved out of the cells. The color change in 
the supernatant from yellow to blue in turn can be measured spectrophotometrically at 
550 nm. The height of absorption correlates with the activity status of the cells [88]. 
 
Procedure: 
Cell culture medium was removed from the plates. 650 mg/mL freshly prepared MTT 
working solution (100 µL/well) was added and incubated for 1 h in the incubator (37°C, 
5% CO2). The supernatant was discarded and 100 µL DMSO was added to each well. 
Consequently the extinction was measured after 15 min incubation, at RT in the dark, 
at 550 nm. 
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2.2.7 Statistical analysis 
 
Raw data were normalized to the control groups and results were expressed as 
mean ± standard error of mean (SEM). For statistical analysis the Student´s t-test was 
performed (Software: GraphPad Prism). P-values < 0.05 were considered to be 
statistically significant. 
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3 Results 
 
3.1 Cell density and morphology 
 
Human ASCs were pre-cultivated for 2 to 3 weeks to a confluence of approximately 
70% (Figure 12a,b). During the experiment, at each selected time point (days 7, 14, 
21, 28) cell morphology was observed microscopically, photographed and saved for 
documentation. Fibroblast-like, spindle-shaped, homogenous and compact looking 
cells were most abundant, especially in samples treated with rhFGF-2 and FGF-2 HIS 
(Figure 13a-h and Figure 14a-h). In comparison, cells treated with the FGF-s3 HIS 
fragment lost their spindle shape and showed a flat morphology, they appeared larger 
and more spread out (Figure 15a-h). 
 
 
 
Figure 12 a-b Preculture: Light microscopic picture of hASCs, 100x. 
Cells cultivated in DMEM Ham`s F12 cell culture medium, a after 5 days 
of culture, b after 10 days of culture. 
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Figure 13 a-h Light microscopic picture of rhFGF-2 treated hASCs, 100x. 
a-d 3 ng/mL rhFGF-2, e-h 30 ng/mL rhFGF-2; timepoints: a, e day 7; b, f 
day 14; c, g day 21; d, h day 28. 
 
 
 
 
Figure 14 a-h Light microscopic picture of FGF-2 HIS treated hASCs, 100x.  
a-d 3 ng/mL rhFGF-2, e-h 30 ng/mL rhFGF-2; timepoints: a, e day 7; b, f 
day 14; c, g day 21; d, h day 28. 
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Figure 15 a-h Microscopic picture of FGF-s3 HIS treated hASCs, 100x.  
a-d 3 ng/mL rhFGF-2, e-h 30 ng/mL rhFGF-2; timepoints: a, e day 7; b, f 
day 14; c, g day 21; d, h day 28. 
 
 
The results of cell counts for all groups on the corresponding days are displayed in 
Figure 16 (3 ng/mL, Figure 16a, 30 ng/mL Figure 16b). Cell numbers of cultures, 
which were treated with FGF-2 HIS and rhFGF-2 increased until day 21 in both, the low 
dose and the high dose groups. Then until day, 28 cell density declined in these 
groups. In the FGF-s3 HIS group no cell density peak was observed, neither in the low 
dose, nor in the high dose samples. Cell density was significantly higher on days 14 
(**p < 0.01), 21 (*p < 0.05) and 28 (*p < 0.05) in cultures, which were supplemented 
with low dose rhFGF-2 in comparison to low dose FGF-s3 HIS cultures (Figure 16a). In 
the high dose group a significant increase of cell density of rhFGF-2 treated cells was 
observed on days 14 (**p < 0.01) and 21 (*p < 0.05) (Figure 16b). Treatment with the 
FGF-2 HIS peptide showed significantly higher values after high dose stimulation, 
compared to the FGF-s3 HIS fragment, on days 7, 21 and 28 (*p < 0.05) (Figure 16b). 
However, no significant increase was observed in low dose FGF-2 HIS groups. 
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Figure 16 a,b Cell density 
Concentration of supplements (FGF-s3 HIS, FGF-2 HIS, rhFGF-2): 
a 3 ng/mL, b 30 ng/mL. Data in [%], normalized to unstimulated cells. 
Results expressed as means ± standard error of mean (SEM), n = 5, *p < 
0.05, **p < 0.01. 
 
 
3.2 Expression of mRNA 
 
Collagen type 1a2, collagen type 3 mRNA expression and the extracellular matrix 
protein markers (vimentin, desmin and alpha smooth muscle actin) were detectable in 
all groups and at all time points studied, whereas collagen type 1a1 mRNA could be 
detected in particular on days 28, especially after FGF-2 HIS treatment (Figure 17a-d 
and Figure 18c,d). In the rhFGF-2 and the FGF-2 HIS groups, low and high dose 
treatment had a similar effect regarding the collagen type 1a1 expression. FGF-2 HIS 
and FGF-s3 HIS treated cells displayed a similar collagen type 1a1 and collagen type 3 
mRNA expression pattern between days 14 to 28. Collagen type 1a2 expression 
showed no significant differences throughout the experiment in all groups. Basically, 
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the results of the FGF-s3 HIS group resembled the results observed in FGF-2 HIS 
samples, though at slightly lower levels. The results of collagen type 1a1 and 3 mRNA 
expression in the rhFGF-2 groups were rather stagnant respectively escalating in a 
more fluctuating manner. All levels of gene expression were normalized to the 
expression of the housekeeping gene GAPDH.  
 
 
 
Figure 17 a-d RT-PCR 
Representative 1.5% agarose gels after electrophoretic separation of RT-
PCR amplicons: a untreated hASCs, b hASCs treated with FGF-s3 HIS, left 
column: 3 ng/mL, right column: 30 ng/mL, c hASCs treated with FGF-2 HIS, 
left column: 3 ng/mL, right column: 30 ng/mL, d hASCs treated with rhFGF-2, 
left column: 3 ng/mL, right column: 30 ng/mL. 
M DNA molecular weight marker, 1 Collagen type 1a2, 2 Collagen type1a1, 3 
Collagen type 3, 4 Vimentin, 6 Alpha smooth muscle actin, 7 GAPDH. 
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Figure 18 a-f mRNA expression of collagen type 1a2, - type 1a1 and -type 3 
Relative expression of collagen type 1a2 (a 3 ng/mL, b 30 ng/mL), collagen 
type 1a1 (c 3 ng/mL, d 30 ng/mL) and collagen type 3 (e 3 ng/mL, f 30 ng/mL). 
Data in [%], normalized to unstimulated cells and GAPDH mRNA levels. 
Results expressed as means ± standard error of mean (SEM), n = 5. 
 
 
The ratios of collagen type 1a2 and collagen type 3, respectively of collagen type 1a1 
and collagen type 3 mRNA expression are displayed in Figure 19a-d. The ratio of 
collagen type 1a1 and collagen type 3 significantly increased on day 21 (*p < 0.05), in 
samples treated with low dose FGF-2 HIS. The ratios of collagen type 1a2 and 
collagen 3 showed no significant differences. It has to be noted, that the results of the 
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collagen type 1a2/-type 3 ratios did not reveal clear trends, indicating high and stable 
collagen type 1a2 mRNA reference levels. 
 
 
 
Figure 19 a-d Ratios of collagen type 1a1/-a2 and collagen type 3 mRNA expression 
Relative collagen type 1a2/collagen type 3 (a 3 ng/mL, b 30 ng/mL) and 
collagen type 1a1/collagen type 3 (c 3 ng/mL, d 30 ng/mL) mRNA expression. 
Data in [%], normalized to unstimulated cells and GAPDH mRNA levels. 
Results expressed as means ± standard error of mean (SEM), n = 5, *p < 0.05. 
 
 
 
The highest vimentin mRNA levels were measured in the presence of high dose FGF-2 
HIS on day 28 (Figure 20a,b). FGF-s3 HIS low- and high dose treatment had a similar 
effect, regarding the vimentin expression, with a peak on day 28. Expression of alpha 
smooth muscle actin mRNA showed again a similar trend, as observed for vimentin 
(Figure 20e,f). Its expression increased on day 28 in all groups, after both- low and 
high dose stimulation. Differences between high and low dose treatment were 
observed, regarding the desmin mRNA levels (Figure 20c,d). Low dose treatment with 
either FGF-s3 HIS, FGF-2 HIS and rhFGF-2 showed increased desmin expression 
levels on day 14. On days 21 and 28 the levels then decreased again. High dose 
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treatment did not show an increase of expression at days 7 to day 14 in the samples 
treated with FGF-s3 HIS and FGF-2 HIS and on day 28 the expression levels declined 
in all groups. 
 
 
 
 
Figure 20 a-f mRNA expression of vimentin, desmin and α-smooth muscle actin 
Relative expression of vimentin (a 3 ng/mL, b 30 ng/mL), desmin (c 3 ng/mL, 
d 30 ng/mL) and α-smooth muscle actin (e 3 ng/mL, f 30 ng /mL). Data in 
[%], normalized to unstimulated cells and GAPDH mRNA levels. Results 
expressed as means ± standard error of mean (SEM), n = 5. 
 
Results 
40 
 
3.3 Apoptosis 
 
The apoptotic and necrotic rates did not differ significantly between the groups and 
studied time points (Figure 21a-d). FACS analysis was performed in two experiments 
(n = 2). Cells showed a polymorphic character and thus protocol set up had to be 
adjusted for each run on negative, unstained cells. It was not possible to induce 
apoptosis in hASCs, for positive controls, by treatment with 1 µg/mL LPS, though a 
marked increase in necrotic cell rates had to be noted in these preparations. Apoptosis 
rate was measured between 3.5 and 19.2% in low dose groups and 10.4 and 19.2% in 
high dose groups. Necrotic rates were measured from 1.0 to 19.4% in low dose groups 
and from 2.2 to 20.3% in high dose groups. The control group showed differing values, 
whereas apoptosis rates were ranging from 2.6 to 13.9% and necrosis rates from 0.2 to 
75.2%. 
 
 
 
Figure 21 a-d Results of FACS analysis upon Annexin V/PI double staining  
a Annexin V, 3 ng/mL b Annexin V, 30 ng/mL  c PI, 3 ng/mL d PI, 30 ng/mL. 
Data in [%], normalized to unstimulated cells. Results expressed as means ± 
standard error of mean (SEM), n = 2. 
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3.4 Proliferation 
 
The results of the BrdU proliferation assay are displayed in Figure 22a,b. The amount 
of BrdU incorporation differed substantially, with highest values measured in the FGF-2 
HIS treated groups. Significantly more detectable BrdU was found in FGF-2 HIS high 
dose samples on days 7 and 14, whereas on days 21 and 28 the levels decreased 
again. Low dose stimulation showed no significant differences between treatment with 
FGF-2 HIS, rhFGF-2 and FGF-s3 HIS.  
 
 
 
Figure 22 a,b Results of BrdU-ELISA 
Concentration supplements (FGF-s3 HIS, FGF-2 HIS, rhFGF-2): a 3 ng/mL, 
b 30 ng/mL. Data in [%], normalized to unstimulated cells. Results 
expressed as means ± standard error of mean (SEM), n = 5, *p < 0.05, 
**p < 0.01. 
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3.5 Viability 
 
Viability of cells was analyzed by determination of mitochondrial activity using MTT. 
Absorbance was directly proportional to the number of living cells. The results of the 
MTT test, which were largely associated with cell density levels, are presented in 
Figure 23a,b. Peak values were measured in low and high dose rhFGF-2 groups on 
days 14 and 21. Viable cell number was significantly increased in rhFGF-2 low dose 
samples on days 14 and 21, and on days 14, 21 and 28 in the high dose group 
(*p < 0.05, **p < 0.01). High dose stimulation with FGF-2 HIS showed same trends, 
with peak values on days 14 and 21, whereas low dose stimulation did not. After day 7, 
OD levels of the FGF-s3 HIS high dose groups were significantly lower in comparison 
to the rhFGF-2 and FGF-2 HIS high dose groups. However, after low dose stimulation 
with FGF-2 HIS and FGF-s3 HIS, extinction levels remained stable and low throughout 
the period of 28 days. 
 
Figure 23 a,b Results of MTT test 
Concentration supplements (FGF-s3 HIS, FGF-2 HIS, rhFGF-2): a 3 ng/mL, 
b 30 ng/mL. Data in [%], normalized to unstimulated cells. Results 
expressed as means ± standard error of mean (SEM), n = 5, *p < 0.05, 
**p < 0.01. 
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4 Discussion 
 
 
Much work has been conducted regarding the effects of hFGF-2 on mesenchymal stem 
cells under various culturing conditions. It was reported that hFGF-2 may induce 
osteogenic differentiation in BM-MSCs in osteogenic medium containing 
dexamethasone [89], whereas in chondrogenic medium 1 ng/mL hFGF-2 was shown to 
accentuate chondrogenesis [90]. In a study by Hankemeier et al. [8] that analyzed the 
effects of low and high dose hFGF-2 treatment on BM-MSCs, without other 
differentiation stimuli, a tendon-like phenotype was displayed. Based on this, we chose 
a similar experimental set up for hASCs. Beyond that we, expanded the study by 
testing different rhFGF-2 variants (rhFGF-2, FGF-2 HIS, FGF-s3 HIS). 
 
4.1 Cell proliferation, density and viability 
 
Cell growth and proliferation are regulated by growth factors, cytokines, culture cell 
density, cell “age” and other environmental factors (pH value, electrolyte concentration 
etc.). Data revealed that cell growth was triggered by rhFGF-2 and FGF-2 HIS, 
whereas the shorter FGF-s3 HIS fragment showed only small proliferative effects on 
hASCs. Increased cell densities were measured after 21 days in rhFGF-2 and FGF-2 
HIS stimulated samples and were then consequently followed by a slight decline in cell 
numbers. This course of kinetics, illustrated in Figure 24, is linked with cell viability 
rates and was observable as well in rhFGF-2, as in FGF-2 HIS groups. Furthermore, 
speaking in a general way, this “relative” growth course was observed with both, 
3 ng/mL and the 30 ng/mL hFGF-2 stimulation. 
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Figure 24 In vitro effects of rhFGF-2 and FGF-2 HIS on hASCs 
Blue line course of kinetics, corresponding with results of cell 
counts, BrdU ELISA and MTT test.  
 
In BM-MSCs, adverse effects have been reported, meaning that in BM-MSCs low dose 
hFGF-2 led to significantly higher cell proliferation and cell density levels than high 
dose FGF-2 [8]. Concerning this, our data are not consistent, as absolute cell numbers 
and viability rates were higher in rhFGF-2 and FGF-2 HIS high dose groups. 
Interestingly, viable cell numbers were higher in FGF-2 HIS high dose groups than in 
FGF-2 HIS low dose groups. This difference between high and low dose treatment was 
not observed in rhFGF-2 and FGF-s3 HIS samples. Although the FGF-2 HIS construct 
is biological active, in comparison to the control peptide rhFGF-2, its effects are more 
dependent on the applied dosage of either 3 ng/mL or 30 ng/mL. Hence, hASCs might 
be more sensitive to different concentrations of FGF-2 HIS respectively higher 
concentration might be needed for achieving similar results, as observed for rhFGF-2. 
This finding might render a practical advantage, as cells could be influenced with   
FGF-2 HIS in altering manner, adaptable to the various situations and requirements. In 
the case of the rhFGF-2 peptide, probably, a lower concentration of 1 ng/mL would 
reveal similar distinct and different impacts on cell proliferation, viability and cell 
density. However, our findings correspond with the assumption that BM-MSCs and 
hASCs are responding in a different way to growth factor stimuli and environmental 
changes, even if both cell types are of mesenchymal origin and display similar 
properties. 
 
Apart from that, we assume that the truncated FGF-s3 HIS fragment showed only little 
biological activities. FGF-s3 HIS does not significantly influence cell numbers, 
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proliferation- and viability rates, neither in low dose, nor in high dose concentration. 
Previously, FGF-s3 HIS was confirmed to be able to bind with high affinity to fibrin and 
fibrinogen [62]. Its weak biological activity might indeed be an advantage for clinical 
applications. The FGF-s3 HIS fragment could be used as a linking partner between 
fibrin and other target substances and therapeutic drugs, without altering cell behaviour 
in vitro or in vivo. 
 
Morphological analyses are in concordance with the results discussed above and 
underline our conclusion. Cultures displayed a spindle-shaped and homogenous 
looking phenotype with low and high dose rhFGF-2. It has to be considered, if a lower 
rhFGF-2 concentration than 3 ng/mL might be more beneficial, as typical cell cluster 
seemed to be more abundant in rhFGF-2 low dose groups.  
Phenotypic differences in the FGF-2 HIS group between low and high dose treatment 
were more distinct. FGF-2 HIS 30 ng/mL treatment revealed clearly a more fibroblast 
like phenotype as 3 ng/mL FGF-2 HIS. As expected, FGF-s3 HIS treated hASCs 
looked considerably flatter and did not build homogenous, spindle-shaped cell clusters, 
neither in 3 ng/mL, nor in 30 ng/mL preparations. 
 
4.2 Apoptosis rates 
 
Data of FACS analysis were not taken into consideration. It was not possible to induce 
apoptosis in the preparations for the positive controls and therefore the obtained data 
were not reliable. Evidence in the literature described that flow cytometry was already 
used successfully for measurement of apoptotic cell rates in mesenchymal stem cells. 
In BM-MSCs rather high apoptosis rates were detected in this context, although they 
were not changed significantly by hFGF-2 treatment [8]. However, we could not set up 
a fitting protocol for all measurements, but had to adjust the settings accordingly for 
each time point. We assume that the problems were due to low cell numbers, 
especially at time points 7 and 14. Therefore, we conclude that in future approaches 
petri dish cultures and higher cell numbers should be used in this context. 
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4.3 mRNA expression 
 
Extracellular matrix (ECM) is building a natural, structural environment which influences 
cellular differentiation, organ morphology, -integrity and -function. Expression of mRNA 
encoding for collagen type 1 and vimentin, which are important elements of ECM, and 
of alpha smooth muscle actin, can be influenced by hFGF-2. A biphasic cellular 
response of consecutive reactions, characterized by an initial trigger of cell growth, 
followed by enhancement of osteogenic cell differentiation processes (Figure 25), have 
been described already in BM-MSCs [8,89]. 
 
 
 
Figure 25 Biphasic cellular respond to hFGF-2 
stimulation 
 
1 (blue line) first phase of proliferation and cell growth,               
2 (red line) second phase: up-regulation of mRNA expression. 
 
 
 
An up-regulation of collagen type 1a1, collagen type 3, vimentin and alpha smooth 
actin mRNA expression was noted after the growth peak between days 21 and 28. 
However, the expression of desmin and collagen type 1a2 mRNA did not follow this 
biphasic response. The desmin gene encodes for a muscle-specific intermediate 
filament expressed by muscle, smooth muscle and cardiac muscle tissues. 
Interestingly, desmin mRNA was expressed earlier than ECM components, resembling 
the course of kinetics shown in Figure 24. Collagen type 1a2 levels were rather high 
from the start, without significant changes, neither at various time points, nor between 
rhFGF-2, FGF-2 HIS and FGF-s3 HIS. Structurally, collagen type 1 forms a 
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characteristic triple helix of two alpha 1 (collagen type 1a1) and one alpha 2 (collagen 
type 1a2) subunits, in a physiological ratio of 2 to 1 [91]. The expression of collagen 
type 1a1 was therefore expected to be approximately two folds higher than collagen 
type 1a2 expression. However, this was not confirmed after evaluation by 
semiquantitative RT-PCR.  
 
By the expression of fibril forming, highly structured collagens, e.g. collagen type 1 and 
3, tensile strength in vertebrate tissue is provided. Collagen type 1 is the major 
component of ECM proteins and most abundant in bone. Mature collagen type 1 is 
highly structured in dense boundless. Collagen type 3 is found in large vessel-, the 
intestine- and the uterine wall. In comparison to collagen type 1, collagen type 3 fibers 
are much thinner [91;92]. After injuries during early stages of wound healing, collagen 
type 3, which can be produced faster, leads to the characteristic scar formation [94]. 
Tensile strength, respectively quality of connective tissue, is influenced by the amount 
of deposited collagen type 1 and 3. A lowered collagen 1/3 ratio is indicative for 
reduced tensile tissue strength and mechanical stability, due to less cross-linkings 
between fibers and a change of geometrical arrangements [93,94]. Hence, not only the 
expression and deposition of ECM proteins is important in tissue engineering of 
tendons, ligaments or bone, but also its quality. We observed a lower ratio of collagen 
type 1a1 and collagen type 3 between days 14 – 21. Linked with the up-regulation of 
mRNA expression, after 28 days, the ratio increased again. This was observed in low 
and high dose groups, although ratios were higher after low dose stimulation. 
Surprisingly, FGF-2 HIS seemed to have a greater impact than rhFGF-2 on hASCs, 
regarding collagen type 1 expression. This could be due, as discussed above, to too 
high rhFGF-2 concentrations.  
The FGF-s3 HIS fragment, which did not enhance cell growth, effected desmin- (with a 
peak on day 14, 21) and alpha smooth muscle actin mRNA expression in similar way, 
as FGF-2 HIS and rhFGF-2. We assume therefore, that cell growth and - differentiation 
might not be linked necessarily in a direct way.  
However, single mRNA expression values fluctuated intensely. In order to be able to 
draw definite conclusions, it would be advisable in future approaches, to change the 
experimental settings from semiquantitative RT-PCR to quantitative Real time PCR.  
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In summary, it can be stated that the use of hASCs promises many perspectives for 
research and clinical applications in allogenic settings. In comparison to hASCs,      
BM-MSCs have a more restricted potential (e.g. low cell number harvest, invasive 
isolation procedure) [15,17]. However, the critical step in this context is still the lack of 
well-characterized adult stem cell population and the full understanding of molecular 
properties and mechanisms [3,33]. Human FGF-2 affects cells in a very complex way, 
regulating different cellular processes [34]. For the time being, based on our data, we 
can confirm that hFGF-2 is able to enhance the expression of important ECM proteins 
and cytoskeletal elements in hASCs. To prove that hFGF-2 triggers the osteogenic 
differentiation potential in hASCs, matrix mineralization and the expression/activity of 
the osteoblastic marker alkaline phosphatase (ALP) needs to be determined in future 
approaches. FGF-2 HIS and rhFGF-2 have different impacts on cells and optimal 
doses have to be adjusted accordingly. The FGF-s3 HIS fragment shows only weak 
biological activities. BM-MSCs and hASCs seem to react in a different way to low and 
high dose hFGF-2 concentrations. In conclusion, the results of our study showed that 
high dose hFGF-2 stimulation enhanced cell growth, whereas low dose hFGF-2 
stressed the differentiation potential of hASCs. We assume that probably a 
combination of an initial high hFGF-2 dosage, followed by low dose hFGF-2 treatment, 
would be most beneficial for tissue engineering approaches.  
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5 Abstract 
 
 
Human adipose derived stem (hASCs) cells, are adult stem cells originated from 
mesenchyme. Somatic stem cells are present in many tissues and organs of the body, 
rendering important function in tissue regeneration. Due to the ability of hASCs, to give 
rise to various mature cell types/tissues and the easy isolation procedure, they have 
been proposed as potential candidates for cell based therapies in the fields of 
regenerative medicine and tissue engineering. 
Human fibroblast growth factor 2 (hFGF-2) is an important growth factor, which 
regulates, among, others cell growth, -differentiation, -proliferation and angiogenesis. 
Human FGF-2 is essential during early embryonic development but also throughout life 
in the regeneration of adult tissues. The FGF family constitutes a group of related 
polypeptides, which are able, upon binding to specific transmembrane receptor tyrosine 
kinases (FGFR), to activate signal pathways, which are associated with cell growth, 
migration and proliferation. Human FGF-2 is produced by various cell types in vivo and 
can be used as culture additive in vitro. 
The aim of the project was, to examine the in vitro effects of different hFGF-2 doses 
(3 ng/mL and 30 ng/mL) on human adipose derived stem cells. Apart from 
commercially available recombinant hFGF-2 (rhFGF-2), additionally the biological 
activities of two self-produced FGF-2 constructs (FGF-2 HIS, FGF-s3 HIS) were 
analyzed over 28 days, regarding cell growth, morphology, viability, apoptosis rates, 
proliferation status and differentiation.  
The results revealed only weak biological effects on cell proliferation, -growth and         
-viability, of the truncated FGF-s3 HIS fragment. As FGF-s3 HIS binds with high affinity 
to fibrin/fibrinogen, the fragment could be used as a linking partner between fibrin and 
drugs, rendering therapeutic issues.  
FGF-2 HIS and rhFGF-2 both increased cell growth and the expression of extracellular 
matrix proteins (e.g. collagen type 1, collagen type 3, vimentin and desmin), which are 
essential hallmarks in engineering of bone, tendons and ligaments. Cells reacted to 
hFGF-2 treatment in a characteristic, biphasic respond, with an initial phase of 
enhanced cell growth. The second phase was marked by an increase of collagen type 
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1, collagen type 3 and vimentin mRNA expression. Morphologically, cells displayed a 
fibroblast like, homogenous looking cell morphology. Differences between low (3 
ng/mL) and high (30 ng/mL) dose hFGF-2 treatment were most distinct in the FGF-2 
HIS group. Highest cell numbers were obtained with 30 ng/mL rhFGF-2. Nevertheless, 
we suggest that low dose hFGF-2 is more suited for osteogenic differentiation. 
However, this hypothesis still remains to be investigated in more detail, probably by 
means of quantitative Real time PCR and using osteogenic medium. We conclude that 
both, FGF-2 HIS and rhFGF-2, are biological active, but they have to be regarded 
separately concerning the administered dosage. 
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6 Zusammenfassung 
 
 
FGF-2 Aktivitäten im Vergleich zu dem FGF-s3-His Fragment in humanen 
Fettstammzellen 
 
 
Humane Fettstammzellen sind adulte, mesenchymale Stammzellen. Prinzipiell sind in 
den meisten Geweben Zellen mit Stammzelleigenschaften zu finden, die dort Aufgaben 
in Bezug auf Geweberegeneration (z.B.: Knochenmark, Darm) erfüllen. Humane 
Fettstammzellen sind zum einen leicht zugänglich (z.B. plastische Chirurgie, 
Abfallprodukt bei Liposuktion) und haben zum anderen die Fähigkeit in verschiedene 
Gewebe zu differenzieren. Somit rückten sie, vor allem im Zusammenhang mit 
zellbasierten Therapien im Bereich der regenerativen Medizin und 
Geweberekonstruktion, immer mehr in den Fokus der biomedizinischen Forschung. Für 
den möglichen, routinemäßigen und klinischen Einsatz von humanen Fettstammzellen 
ist es wichtig, das Wissen der zugrunde liegenden molekularen Mechanismen und 
physiologischen Zusammenhänge von Wachstum und Differenzierung zu untersuchen. 
Humaner Fibroblasten Wachstumsfaktor (hFGF-2) ist ein wichtiger Wachstumsfaktor 
durch den unter anderem Vorgänge wie Zellwachstum und -differenzierung, 
Gewebereparatur und -regeneration (Knorpel-, Nervengewebe) sowie Angiogenese 
induziert beziehungsweise gesteuert werden können. In diesem Zusammenhang ist 
seine Rolle vor allem in der Embryonalentwicklung, aber auch in adulten Geweben 
tragend. Die FGF-Familie stellt eine Gruppe von Signalproteinen dar, die spezifische 
Rezeptor-Tyrosin Kinasen an Zelloberflächen binden (FGF-Rezeptoren, FGFR) und 
durch eine Signaltransduktionskaskade ins Zellinnere FGF Zielgene aktivieren. 
Humaner FGF-2 beeinflusst somit die Zellphysiologie und kann als in vitro 
Zellstimulans verwendet werden. 
Ziel des Projekts war es, die Auswirkungen von rekombinantem hFGF-2 auf die in vitro 
Proliferation bzw. Differenzierung von adulten Stammzellen (humanen 
Fettstammzellen) zu untersuchen. Es wurden zwei verschiedene hFGF-2 
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Konzentrationen, niedrig (3 ng/mL) und hoch (30 ng/mL), eingesetzt und die 
stimulierten Zellen folglich 28 Tage lang beobachtet. Weiters wurde die Aktivität von 
den 2 eigens produzierten und aufgereinigten FGF-(Teil)peptiden FGF-2 HIS und FGF-
s3 HIS untersucht und mit dem kommerziell erhältlichen, rekombinanten hFGF-2  
(rhFGF-2) verglichen.  
Die Ergebnisse zeigten eine nur schwache biologische Aktivität des FGF-s3 HIS 
Fragments im Vergleich zu rhFGF-2 und FGF-2 HIS. FGF-s3 HIS bindet mit hoher 
Affinität an Fibrin/Fibrinogen, und könnte somit in Zukunft als Bindungspartner 
zwischen Fibrin und anderen Zielsubstanzen (z.B. Medikamente) für therapeutische 
Zwecke eingesetzt werden. 
Im Gegensatz dazu, förderten FGF-2 HIS und rhFGF-2 das Zellwachstum und die die 
Expression von Proteinen der extrazellulären Matrix. Alle drei Punkte sind essentiell für 
die Gewebekonstruktion (Tissue Engineering) von Knochen, Sehnen und Bändern. 
Zwei Phasen der Zellantwort waren zu beobachten, ein Anstieg des Zellwachstums 
und der Proliferationsraten zwischen Tag 14 und 21, beziehungsweise die Erhöhung 
der Expression von Kollagen Type 1, Kollagen Type 3 und Vimentin ab Tag 21. 
Histologisch äußerte sich die hFGF-2 Behandlung in einer fibroblastischen, homogen 
wirkenden Zellmorphologie. Unterschiede zwischen 3 ng/mL und 30 ng/mL hFGF-2 
Behandlungen wurden vor allem in der FGF-2 HIS Gruppe deutlich. Obwohl 30 ng/mL 
hFGF-2 höhere Zellzahlen und biologische Aktivität hervorbrachte, vermuten wir, dass 
sich eine Dosis von 3 ng/mL hFGF-2 besser auf die osteogene Differenzierung 
auswirkt. Diese Hypothese muss allerdings noch durch genauere Methoden, wie 
quantitative Real time PCR, die Bestimmung der alkalischen Phosphatase (ALP) bzw. 
durch den Nachweis mineralisierter Matrix verifiziert werden. Die Peptide rhFGF-2 und 
FGF-2 HIS müssen in Hinsicht der eingesetzten Konzentrationen gesondert betrachtet 
werden und rhFGF-2 sollte in einer noch geringeren Konzentration von 1 ng/mL 
getestet werden. Jedenfalls wurde die Vermutung bestätigt, dass meschenchymale 
Stammzellen aus humanem Fettgewebe beziehungsweise aus dem Knochenmark, 
unterschiedlich sensibel auf verschiedene hFGF-2 Konzentrationen reagieren. 
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8 Appendix 
 
 
DNA molecular weight markers (Figure 26) 
 
 
 
 
Figure 26 GeneRulerTMDNA-Ladder (Fermentas) 
left middle range, 5000 – 100 bp 
 
right low range, 1500 – 50 bp. 
 
 
 
Nucleotide blast 
 
Collagen 1a2 
Sense: Homo sapiens collagen, type 1, alpha 2, mRNA (cDNA clone MGC:57503), 
complete cds, length = 5060 
 
Score = 40.1 bits (20), Expect = 0.027, Identities = 20/20 (100%), Gaps = 0/20 (0%), 
Strand=Plus/Plus 
 
Query  1     GAAAACATCCCAGCCAAGAA  20 
             |||||||||||||||||||| 
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Sbjct  3725  GAAAACATCCCAGCCAAGAA  3744 
 
Antisense: Homo sapiens collagen, type 1, alpha 2, mRNA (cDNA clone MGC:57503), 
complete cds, length = 5060 
 
Score = 40.1 bits (20), Expect = 0.027, Identities = 20/20 (100%), Gaps = 0/20 (0%), 
Strand=Plus/Minus 
 
Query  1     CAGGTTGCCAGTCTCCTCAT  20 
             |||||||||||||||||||| 
Sbjct  3958  CAGGTTGCCAGTCTCCTCAT  3939 
 
Collagen 1a1 
Sense: Homo sapiens collagen, type 1, alpha 1, mRNA (cDNA clone MGC:33668), 
complete cds, length = 4752 
 
Score = 36.2 bits (18), Expect = 0.42, Identities = 18/18 (100%), Gaps = 0/18 (0%), 
Strand=Plus/Plus 
 
Query  1    TGACGAGACCAAGAACTG  18 
            |||||||||||||||||| 
Sbjct  341  TGACGAGACCAAGAACTG  358 
 
Antisense: Homo sapiens collagen, type 1, alpha 1, mRNA (cDNA clone MGC:33668), 
complete cds, length = 4752 
 
Score = 40.1 bits (20), Expect = 0.027, Identities = 20/20 (100%), Gaps = 0/20 (0%), 
Strand=Plus/Minus 
 
Query  1    CCATCCAAACCACTGAAACC  20 
            |||||||||||||||||||| 
Sbjct  940  CCATCCAAACCACTGAAACC  921 
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Collagen 3 
Sense: Homo sapiens collagen, type 3, alpha , (COL3A1), mRNA, length = 5489 
 
Score = 38.2 bits (19), Expect = 0.11, Identities = 19/19 (100%), Gaps = 0/19 (0%), 
Strand=Plus/Plus 
 
Query  1     CAGGTGAACGTGGAGCTGC  19 
             ||||||||||||||||||| 
Sbjct  3407  CAGGTGAACGTGGAGCTGC  3425 
 
Antisense: Homo sapiens collagen, type 3, alpha 1, mRNA, length = 5489 
 
Score = 36.2 bits (18), Expect = 0.42, Identities = 18/18 (100%), Gaps = 0/18 (0%), 
Strand=Plus/Minus 
 
Query  3     CCACCAGTGTTTCCGTGG  20 
             |||||||||||||||||| 
Sbjct  4065  CCACCAGTGTTTCCGTGG  4048 
 
Vimentin 
Sense: Human mRNA for vimentin, length = 1766 
 
Score = 40.1 bits (20), Expect = 0.027, Identities = 20/20 (100%), Gaps = 0/20 (0%),  
Strand=Plus/Plus 
 
Query  1    CTGCCAACCGGAACAATGAC  20 
            |||||||||||||||||||| 
Sbjct  945  CTGCCAACCGGAACAATGAC  964 
 
Antisense: Human mRNA for vimentin, length = 1766 
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Score = 42.1 bits (21), Expect = 0.010, Identities = 21/21 (100%), Gaps = 0/21 (0%), 
Strand=Plus/Minus 
 
Query  1     CACGAAGGTGACGAGCCATTT  21 
             ||||||||||||||||||||| 
Sbjct  1187  CACGAAGGTGACGAGCCATTT  1167 
 
Desmin 
Sense: Homo sapiens desmin (DES), mRNA, length = 2268 
 
Score = 58.0 bits (29), Expect = 6e-07, Identities = 29/29 (100%), Gaps = 0/29 (0%),  
Strand=Plus/Plus 
 
Query  1     ATGTGGAGATTGCCACCTACCGGAAGCTG  29 
             ||||||||||||||||||||||||||||| 
Sbjct  1282  ATGTGGAGATTGCCACCTACCGGAAGCTG  1310 
 
Antisense: Homo sapiens desmin (DES), mRNA, length=2268 
 
Score = 56.0 bits (28), Expect = 2e-06, Identities = 28/28 (100%), Gaps = 0/28 (0%), 
Strand=Plus/Minus 
 
Query  1     GTGTCCTGGGATGGAAGAAGGCTGGCTT  28 
             |||||||||||||||||||||||||||| 
Sbjct  1584  GTGTCCTGGGATGGAAGAAGGCTGGCTT  1557 
 
a-SMA 
Sense: Homo sapiens actin, alpha 2, smooth muscle, aorta (ACTA2), mRNA, length = 
1330 
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Score = 42.1 bits (21), Expect = 0.010, Identities = 21/21 (100%), Gaps = 0/21 (0%), 
Strand=Plus/Plus 
 
Query  1    GAACATGGCATCATCACCAAC  21 
            ||||||||||||||||||||| 
Sbjct  267  GAACATGGCATCATCACCAAC  287 
  
Antisense: Homo sapiens actin, alpha 2, smooth muscle, aorta (ACTA2), mRNA, length 
= 1415 
 
Score = 40.1 bits (20), Expect = 0.015, Identities = 20/20 (100%), Gaps = 0/20 (0%), 
Strand = Plus/Plus 
 
Query  1     CGACCGAATGCAGAAGGAGA  20 
             |||||||||||||||||||| 
Sbjct  1052  CGACCGAATGCAGAAGGAGA  1071 
 
GAPDH 
Sense: Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GAPDH), mRNA, 
length = 1310 
 
Score = 38.2 bits (19), Expect = 0.038, Identities = 19/19 (100%), Gaps = 0/19 (0%), 
Strand=Plus/Plus 
 
Query  1    TTAGCACCCCTGGCCAAGG  19 
            ||||||||||||||||||| 
Sbjct  571  TTAGCACCCCTGGCCAAGG  589 
 
Antisense: 
Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GAPDH), mRNA, length = 
1310 
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Score = 40.1 bits (20),  Expect = 0.015, Identities = 20/20 (100%), Gaps = 0/20 (0%), 
Strand=Plus/Minus 
 
Query  1     CTTACTCCTTGGAGGCCATG  20 
             |||||||||||||||||||| 
Sbjct  1111  CTTACTCCTTGGAGGCCATG  1092 
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